Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. Show more
Location: 126 East Lincoln Avenue, Rahway, NJ, 07065, United States | Website: https://www.merck.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
199B
52 Wk Range
$73.31 - $114.79
Previous Close
$79.67
Open
$79.78
Volume
14,885,642
Day Range
$77.58 - $79.88
Enterprise Value
225.8B
Cash
8.622B
Avg Qtr Burn
N/A
Insider Ownership
0.07%
Institutional Own.
80.58%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PADCEV® (enfortumab vedotin-ejfv) + KEYTRUDA® (pembrolizumab) Details Solid tumor/s, Cancer, Urothelial cancer | Approved Update | |
GARDASIL 9 Details Human Papillomavirus 9-valent Vaccine, Human papillomavirus | Approved Update | |
M-M-R®II, VARIVAX®, and ProQuad® Details Vaccine, Viral infection | Approved Update | |
KEYTRUDA Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Approved Update | |
KEYTRUDA+ chemotherapy Details Cancer, Mesothelioma, Malignant pleural/peritoneal mesothelioma | Approved Update | |
KEYTRUDA in comb w/chemotherapy Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Approved Quarterly sales | |
ENFLONSIA (clesrovimab-cfor) Details Respiratory syncytial virus | Approved Quarterly sales | |
KEYTRUDA+ Padcev (enfortumab vedotin) Details Cancer, Urothelial carcinoma | Approved Quarterly sales | |
TUKYSA (Tucatinib) Details Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer | Approved Quarterly sales | |
Clesrovimab (MK-1654) Details Respiratory syncytial virus | Approved Quarterly sales | |
KEYTRUDA® (pembrolizumab) Details Head and neck squamous cell carcinoma | Approved Quarterly sales | |
KEYTRUDA+ chemotherapy Details Cancer, Biliary Tract Cancer | Approved Quarterly sales | |
KEYTRUDA+ trastuzumab+ chemotherapy Details Gastric cancer, Cancer, Gastroesophageal adenocarcinomas | Approved Quarterly sales | |
CAPVAXIVE (V116) Details Pneumococcal Conjugate Vaccine | Approved Quarterly sales | |
ERVEBO Details Ebola | Approved Quarterly sales | |
PREVYMIS™ (letermovir) Details Cytomegalovirus, Viral infection | Approved Quarterly sales | |
KEYTRUDA + chemotherapy Details Cancer, Gastroesophageal adenocarcinomas, Gastric cancer | Approved Quarterly sales | |
WINREVAIR™ (sotatercept-csrk) Details Pulmonary arterial hypertension | Approved Quarterly sales | |
Approved Quarterly sales | ||
WELIREG® (belzutifan) Details Renal cell carcinoma, von Hippel-Lindau, Cancer, Hemangioblastoma, Pancreatic neuroendocrine tumors | Approved Quarterly sales | |
KEYTRUDA in comb w/ EBRT + brachytherapy Details Cervical cancer, Cancer | Approved Quarterly sales | |
LYNPARZA(olaparib) + abi/pred Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Approved Quarterly sales | |
WELIREG® (belzutifan) Details Pheochromocytoma , Paraganglioma | Approved Quarterly sales | |
KEYTRUDA +carboplatin + paclitaxel Details Cancer, Solid tumor/s, Carcinoma , Endometrial cancer | Approved Quarterly sales | |
KEYTRUDA (pembrolizumab) injection Details Gastric cancer, Gastroesophageal adenocarcinomas | PDUFA Approval decision | |
Doravirine / Islatravir (DOR/ISL) Details Virologically Suppressed HIV-1 Infection | PDUFA Approval decision | |
WINREVAIR™ (sotatercept-csrk) Details Pulmonary arterial hypertension | PDUFA Approval decision | |
Gefapixant (MK-7264) Details Chronic cough | NDA FDA meeting | |
MK-1084 +/- KEYTRUDA® Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Tulisokibart (PRA023) (Anti-TL1A mAb) Details Crohns disease | Phase 3 Data readout | |
Tulisokibart (MK-7240) (PRA023) (Anti-TL1A mAb) Details Irritable bowel syndrome, Crohns disease, Ulcerative colitis | Phase 3 Data readout | |
KEYTRUDA+pemetrexed Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Ifinatamab Deruxtecan (I-DXd) Details Pretreated Metastatic Castration-Resistant Prostate Cancer | Phase 3 Data readout | |
LAGEVRIO™ (molnupiravir) Details Viral infection, COVID-19 | Phase 3 Data readout | |
Ifinatamab Deruxtecan (I-DXd) Details Esophageal Squamous Cell Carcinoma | Phase 3 Data readout | |
Ifinatamab Deruxtecan (I-DXd) Details Small cell lung cancer, Cancer | Phase 3 Data readout | |
MK-2870 Details Non-small cell lung carcinoma, Cancer | Phase 3 Data readout | |
Nemtabrutinib Details Cancer, Small lymphocytic lymphoma , Chronic lymphocytic leukemia | Phase 3 Data readout | |
MK-5684 (ODM-208) Details Cancer, Castration-resistant prostate cancer | Phase 3 Data readout | |
Bomedemstat Details Thrombocythemia | Phase 3 Data readout | |
V181 Details Dengue Vaccine | Phase 3 Data readout | |
Bomedemstat Details Thrombocytopenia | Phase 3 Data readout | |
Patritumab deruxtecan (HER3-DXd) Details Breast cancer, Cancer | Phase 3 Data readout | |
Patritumab deruxtecan (HER3-DXd) Details Non-small cell lung carcinoma | Phase 3 Data readout | |
KEYTRUDA Details Cancer, Solid tumor/s, Urothelial carcinoma | Phase 3 Update | |
Enlicitide Decanoate (Previously MK-0616) Details Cardiovascular disease , Hypercholesterolemia | Phase 3 Update | |
KEYTRUDA + LENVIMA Details Cancer, Renal cell carcinoma | Phase 3 Update | |
KEYTRUDA® (pembrolizumab)+ LYNPARZA® (olaparib) Details Cancer, Non-small cell lung carcinoma | Phase 3 Update | |
Phase 3 Update | ||
MK-1084 + cetuximab + mFOLFOX6 Details unresectable or metastatic CRC | Phase 3 Update | |
Zilovertamab (MK-2140) Details Previously Untreated Diffuse large B cell lymphoma | Phase 3 Update | |
KEYTRUDA Details Cancer, Renal cell carcinoma | Phase 3 Update | |
KEYTRUDA Details Solid tumor/s, Cancer, Triple-negative breast cancer , Breast cancer | Phase 3 Update | |
KEYTRUDA +LENVIMA® (lenvatinib) Details Cancer, Carcinoma , Endometrial cancer | Phase 3 Update | |
KEYTRUDA + favezelimab Details Cancer, Metastatic colorectal cancer | Phase 3 Update | |
KEYTRUDA® plus paclitaxel +/- bevacizumab Details Platinum-Resistant Recurrent Ovarian Cancer | Phase 3 Update | |
KEYTRUDA +LENVIMA® (lenvatinib) Details Cancer, Non-small cell lung carcinoma | Phase 3 Update | |
KEYTRUDA + LENVIMA in comb w/TACE Details Cancer, Hepatocellular carcinoma | Phase 3 Update | |
KEYTRUDA Details Cancer, Solid tumor/s, ER+/HER2- breast cancer | Phase 3 Update | |
MK-8527 Details HIV-1 PrEP | Phase 3 Initiation | |
Enlicitide Decanoate (Previously MK-0616) Details Hypercholesterolemia | Phase 3 Initiation | |
Raludotatug Deruxtecan Details Platinum-resistant ovarian cancer, Cancer | Phase 2/3 Data readout | |
Restoret (MK-3000, formerly EYE103) Details Eye disease , Diabetic macular edema | Phase 2/3 Data readout | |
Zilovertamab (MK-2140) Details r/r Diffuse large B cell lymphoma | Phase 2/3 Update | |
Efinopegdutide (MK-6024) Details Non-Alcoholic Fatty Liver Disease, Liver disease | Phase 2b Initiation | |
Bomedemstat Details Myelofibrosis | Phase 2 Data readout | |
PRA023 (Anti-TL1A mAb) Details Autoimmune disease, Systemic sclerosis | Phase 2 Update | |
Ifinatamab Deruxtecan (I-DXd) Details Small cell lung cancer, Cancer | Phase 2 Update | |
Belzutifan + cabozantinib Details Cancer, Renal cell carcinoma | Phase 2 Update | |
PRA023 (Anti-TL1A mAb) Details Systemic sclerosis, Autoimmune disease | Phase 2 Update | |
HPN328 (DLL3) +/- atezolizumab Details Cancer, Small cell lung cancer, Solid tumor/s | Phase 1/2 Update | |
MK-1084 Details Colorectal cancer, Non-small cell lung carcinoma | Phase 1 Update | |
PRA052 Details Inflammatory bowel disease | Phase 1 Update | |
HPN217 (BCMA) Details Multiple myeloma | Phase 1 Update | |
KEYTRUDA + LENVIMA Details Cancer, Head and neck squamous cell carcinoma | Failed Discontinued | |
KEYTRUDA+ enzalutamide + androgen deprivation therapy (ADT) Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Failed Discontinued |